Biofrontera Stock Price, News & Analysis

Biofrontera Inc. (NASDAQ:BFRI) reported record financial results for fiscal year 2024, achieving total revenues of $37.3 million, a 9.5% increase from 2023. Q4 2024 revenue grew 18.5% to $12.6 million.

Key highlights include: reduced operating expenses to $54.5 million (down 3.9%), improved cash position to $5.9 million, and restructured agreements resulting in Ameluz® transfer price reduction from 50% to 25%. The company successfully placed 100 RhodoLED® XL lamps since June 2024 launch.

Notable achievements include FDA approval for using up to three Ameluz® tubes per treatment, significant Phase 3 study results for Superficial Basal Cell Carcinoma treatment, and accelerated patient recruitment in clinical trials. However, the company reported a net loss of $(17.8) million for 2024, though improved from $(20.1) million in 2023.

Biofrontera (Nasdaq: BFRI) has completed patient enrollment in its Phase 3 clinical trial evaluating Ameluz® for treating mild to moderate actinic keratoses (AKs) on extremities, neck and trunk. The study enrolled 172 patients in a 4:1 ratio receiving either Ameluz® or vehicle gel.

This multicenter, randomized, double-blind study will assess the safety and efficacy of Ameluz® PDT using 1-3 tubes over surface areas of 80-240cm². Patients receive one PDT treatment, with a second treatment at 12 weeks if AK lesions remain, followed by a one-year monitoring period.

The treatment phase is expected to complete by September 2025, with follow-up concluding in Q2 2026. Upon positive outcomes, Biofrontera plans to submit a supplemental New Drug Application to the FDA in second half of 2026.

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products, has scheduled its fourth quarter and full year 2024 financial results announcement for March 21, 2025. The results will be released before market opening, followed by a conference call at 10:00am Eastern Time.

The company specializes in the commercialization of Ameluz® with the RhodoLED® lamp series for photodynamic therapy (PDT) of actinic keratosis (AK), which are pre-cancerous skin lesions. Biofrontera is also conducting clinical trials to expand these products' applications for treating non-melanoma skin cancers and moderate to severe acne.

Biofrontera Inc. (BFRI) has achieved a significant milestone in its Phase 3 study of Ameluz-PDT for treating superficial Basal Cell Carcinoma (sBCC), with the last patient completing the 1-year follow-up in December 2024. The study, involving 187 patients, demonstrated highly statistically significant results (p <0.0001) for all primary and secondary endpoints in October 2024.

The double-blind, randomized, placebo-controlled trial evaluated patients with confirmed sBCC who received either Ameluz-PDT or placebo-PDT treatments. The company plans to submit an sNDA to the FDA in Q3 2025, including the one-year follow-up data. While this data supports the FDA submission, patients will be monitored for a total of five years due to risks of local recurrence.

BCC represents the most common skin cancer in the US, with over 3 million cases annually, making this potential treatment expansion significant for Biofrontera's market presence.

Biofrontera Inc. (BFRI) announced the successful placement of its 100th RhodoLED® XL Lamp in the US market since its commercial launch in June 2024. The device, FDA-approved in 2022 for use with Ameluz® gel for photodynamic therapy (PDT) of actinic keratoses, has seen rapid adoption with more than 10% of Ameluz-using offices installing the system.

The RhodoLED XL features more LED panels than its predecessor BF-RhodoLED, enabling treatment of larger surface areas in a single session. Dr. Aaron Hoover of Front Range Dermatology highlighted the lamp's design, maneuverability, and enhanced patient throughput. Following FDA approval in October 2024, physicians can now use up to 3 tubes of Ameluz® in one treatment, maximizing the benefits of the larger illumination area.

Biofrontera (Nasdaq: BFRI) has completed a private placement of a $4.2 million senior secured convertible note with its principal shareholders. The note matures on November 22, 2027, with a 10% annual PIK interest rate and is secured by company assets. The note is convertible to common shares at $0.78 per share at holder's discretion, or automatically if the 10-day VWAP exceeds $2.50. The financing includes restrictive covenants limiting the company's ability to create liens, pay dividends, incur debt, or enter affiliate transactions. Proceeds will support general operations and strategic investments, including commercial and clinical development initiatives.

Biofrontera reported Q3 2024 revenues of $9.0 million, up 1.5% from Q3 2023, with potential 19% growth impacted by Hurricane Milton delays. Nine-month revenues reached $24.8 million, showing 5.6% growth. Ameluz achieved record volume in September 2024, while SG&A expenses decreased 14% year-over-year. The company successfully launched RhodoLED XL with 39 installations since June 2024. Notable developments include FDA approval to increase Ameluz dosage to three tubes per treatment and highly significant Phase 3 sBCC study results showing 75.9% histological clearance versus 19% with placebo.

Biofrontera announced significant results from its Phase 3 study of Ameluz®-PDT for treating superficial basal cell carcinoma (sBCC). The study involved 187 patients and showed 65.5% success rate with Ameluz®-PDT compared to 4.8% with placebo in achieving complete clinical and histological clearance. Secondary endpoints were also highly significant (p<0.0001), with 64.1% of Ameluz®-PDT patients achieving total clearance of all sBCC lesions versus 4.8% for placebo. Patient satisfaction was notable, with 64.3% rating the treatment as very good and 22.2% as good. The company plans to submit FDA documentation in Q2/Q3 2025 after completing the one-year follow-up phase in December.

Biofrontera Inc. (Nasdaq: BFRI) has announced the database lock for its Phase 3 study ALA-BCC-CT013, evaluating Ameluz®-Photodynamic Therapy (PDT) for treating superficial Basal Cell Carcinoma (sBCC). This marks the end of data collection for the treatment phase, with analysis now underway. The study, involving 186 patients, is the first Phase 3 PDT trial for sBCC in the United States.

Key points:

• Double-blind, randomized, placebo-controlled multi-center study
• Primary endpoint: complete clinical and histological clearance of target BCC lesion
• Interim results expected November 2024
• FDA submission targeted for Q1 2025, including 1-year follow-up data

If approved, this would expand Biofrontera's label from premalignant applications to treating cutaneous malignancy, advancing their goal of becoming market leaders in PDT.